Hayley Wheeler Leatham, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Leatham’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A151279 · Current
Licensed to practise in California · since 2017 · expires 2027-04-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$248,161
Medicare paid this office $248,161 for 661 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 424 | $65,527 | $111 |
| Biopsy of related skin growth, first growth | 258 | $28,016 | $90 |
| Destruction of precancer skin growth, 1 growth | 357 | $21,349 | $47 |
| Destruction of skin growth, 1-14 growths | 127 | $18,928 | $109 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 47 | $16,790 | $300 |
See all 19 services
| Return visit (30+ min) | 424 | $65,527 | $111 |
| Biopsy of related skin growth, first growth | 258 | $28,016 | $90 |
| Destruction of precancer skin growth, 1 growth | 357 | $21,349 | $47 |
| Destruction of skin growth, 1-14 growths | 127 | $18,928 | $109 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 47 | $16,790 | $300 |
| Short return visit (20+ min) | 128 | $12,419 | $76 |
| Destruction of precancer skin growth, 2-14 growths | 291 | $11,671 | $7 |
| New patient visit (30+ min) | 122 | $10,251 | $84 |
| Biopsy of related skin growth, each additional growth | 108 | $8,147 | $47 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 15 | $6,739 | None |
| Destruction of precancer skin growth, 15 or more growths | 26 | $5,410 | $164 |
| Punch biopsy, first skin growth | 39 | $4,650 | $116 |
| New patient visit (15+ min) | 63 | $3,942 | $63 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 22 | $3,324 | $138 |
| Short return visit | 52 | $2,930 | $51 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 17 | $2,217 | $123 |
| Injection into skin growth, 1-7 growths | 29 | $1,993 | $47 |
| Application of light to destroy precancer skin growth | 13 | $1,963 | $151 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 29 | $49 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 46 | More than 86% of doctors who do this |
| Removal of skin lesions | 1228 | More than 95% of doctors who do this |
| Removal or shaving of skin growth | 17 | More than 70% of doctors who do this |
| Skin biopsy | 494 | More than 95% of doctors who do this |
Who their Medicare patients are
661 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 10% · Women 54% · Also on Medicaid 13% · Health risk score 1.10. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 68% · Diabetes 24% · Chronic kidney disease 24% · Coronary heart disease 21% · Cancer 18% · Depression 15% · Atrial fibrillation 13% · COPD 12% · Heart failure 11% · Dementia 5% · Stroke 5%.
The office billed $1,211,250, Medicare allowed $335,768 and paid $248,161; for 4,558 services of 45 kinds; $8,034 of it was for drugs given in the office and $240,127 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 661 | 4,558 | 74 | 1.10 | $1,211,250 | $248,161 |
| 2023 | 574 | 3,658 | 72 | 1.13 | $980,991 | $218,511 |
| 2022 | 467 | 2,572 | 73 | 1.13 | $675,131 | $150,249 |
| 2021 | 273 | 1,320 | 72 | 1.28 | $346,510 | $80,442 |
| 2020 | 96 | 290 | 73 | 1.75 | $86,889 | $19,701 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 22 services
| Return visit (30+ min) | 333 | $53,752 | $111 |
| Biopsy of related skin growth, first growth | 207 | $24,230 | $95 |
| Destruction of precancer skin growth, 1 growth | 278 | $17,202 | $45 |
| New patient visit (30+ min) | 174 | $16,872 | $97 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 38 | $14,412 | $307 |
| Destruction of skin growth, 1-14 growths | 88 | $13,116 | $111 |
| Short return visit (20+ min) | 110 | $9,814 | $77 |
| Destruction of precancer skin growth, 2-14 growths | 232 | $9,113 | $7 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 15 | $7,790 | None |
| Biopsy of related skin growth, each additional growth | 74 | $7,059 | $51 |
| Punch biopsy, first skin growth | 32 | $3,931 | $119 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 23 | $3,576 | $138 |
| New patient visit (15+ min) | 57 | $3,354 | $59 |
| Destruction of precancer skin growth, 15 or more growths | 16 | $2,837 | $167 |
| Application of light to destroy precancer skin growth | 16 | $2,608 | $153 |
| Short return visit | 39 | $2,286 | $53 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 12 | $1,965 | $140 |
| Injection into skin growth, 1-7 growths | 31 | $1,811 | $42 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 11 | $1,465 | $122 |
| Telehealth originating site facility fee | 47 | $1,121 | $22 |
| Punch biopsy, each additional skin growth | 11 | $780 | $60 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 27 | $51 | None |
2022: 18 services
| Return visit (30+ min) | 207 | $31,107 | $112 |
| New patient visit (30+ min) | 217 | $19,056 | $88 |
| Biopsy of related skin growth, first growth | 169 | $18,512 | $93 |
| Destruction of precancer skin growth, 1 growth | 193 | $10,976 | $45 |
| Biopsy of related skin growth, each additional growth | 80 | $7,093 | $50 |
| Destruction of skin growth, 1-14 growths | 56 | $6,745 | $114 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 21 | $6,497 | $295 |
| Short return visit (20+ min) | 68 | $6,192 | $80 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 12 | $6,156 | None |
| Destruction of precancer skin growth, 2-14 growths | 162 | $6,022 | $7 |
| New patient visit (15+ min) | 76 | $4,293 | $56 |
| Punch biopsy, first skin growth | 32 | $3,759 | $111 |
| Application of light to destroy precancer skin growth | 12 | $2,031 | $156 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $1,457 | $121 |
| Injection into skin growth, 1-7 growths | 16 | $1,039 | $49 |
| Short return visit | 16 | $964 | $54 |
| Telehealth originating site facility fee | 41 | $921 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $25 | None |
2021: 14 services
| New patient visit (30+ min) | 148 | $14,886 | $101 |
| Return visit (30+ min) | 93 | $14,565 | $121 |
| Biopsy of related skin growth, first growth | 83 | $8,922 | $95 |
| New patient visit (45+ min) | 45 | $6,459 | $144 |
| Destruction of precancer skin growth, 1 growth | 98 | $5,806 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 81 | $3,276 | $7 |
| Destruction of skin growth, 1-14 growths | 26 | $3,010 | $108 |
| Biopsy of related skin growth, each additional growth | 37 | $2,981 | $52 |
| Short return visit (20+ min) | 25 | $2,255 | $87 |
| Punch biopsy, first skin growth | 17 | $2,139 | $126 |
| New patient visit (15+ min) | 15 | $1,049 | $70 |
| Injection into skin growth, 1-7 growths | 13 | $817 | $48 |
| Telehealth originating site facility fee | 35 | $773 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $18 | None |
2020: 8 services
| New patient visit (30+ min) | 57 | $5,840 | $102 |
| Return visit (30+ min) | 18 | $1,967 | $104 |
| Biopsy of related skin growth, first growth | 17 | $1,466 | $77 |
| Destruction of skin growth, 1-14 growths | 12 | $1,372 | $114 |
| New patient visit (15+ min) | 18 | $1,313 | $73 |
| Destruction of precancer skin growth, 1 growth | 23 | $1,116 | $49 |
| Telehealth originating site facility fee | 32 | $682 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $361 | $6 |
Medicaid work
$1,411 in 2023
Medicaid paid $1,411 for 25 billed services this clinician did in 2023, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 25 | $1,411 |
| 2023 | 25 | 1 | 13 | $1,411 |
| 2021 | 16 | 1 | 15 | $506 |
| 2020 | 29 | 1 | 16 | $817 |
See the largest Medicaid services in earlier years
2021
| Telehealth originating site facility fee | 16 | $506 |
2020
| Telehealth originating site facility fee | 29 | $817 |
Drugs they prescribed that Part D paid
$654,576
Pharmacies billed $654,576 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,236) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,150 generic and 86 brand-name prescriptions · $654,576 in drug cost · 77 antibiotic prescriptions to 40 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Skyrizi | 22 | $471,639 | $21,438 |
| Dupixent | 17 | $61,424 | $3,613 |
| Clobetasol Propionate | 89 | $5,043 | $57 |
| Fluocinonide | 122 | $4,794 | $39 |
| Fluorouracil | 50 | $3,301 | $66 |
See all 22 drugs
| Skyrizi | 22 | $471,639 | $21,438 |
| Dupixent | 17 | $61,424 | $3,613 |
| Clobetasol Propionate | 89 | $5,043 | $57 |
| Fluocinonide | 122 | $4,794 | $39 |
| Fluorouracil | 50 | $3,301 | $66 |
| Metronidazole | 51 | $2,294 | $45 |
| Clindamycin Phosphate | 62 | $1,892 | $31 |
| Tacrolimus | 20 | $1,847 | $92 |
| Ketoconazole | 117 | $1,682 | $14 |
| Doxycycline Hyclate | 56 | $1,494 | $27 |
| Ciclopirox | 37 | $1,453 | $39 |
| Tretinoin | 13 | $973 | $75 |
| Triamcinolone Acetonide | 106 | $893 | $8 |
| Betamethasone Dipropionate | 13 | $882 | $68 |
| Nystatin | 70 | $818 | $12 |
| Valacyclovir | 22 | $667 | $30 |
| Hydrocortisone | 124 | $521 | $4 |
| Desonide | 16 | $499 | $31 |
| Mupirocin | 46 | $335 | $7 |
| Minoxidil | 20 | $305 | $15 |
| Cephalexin | 14 | $298 | $21 |
| Hydroxyzine | 16 | $109 | $7 |
Year by year
| 2024 | 1,236 | 367 | 0% (0) | 7% | $654,576 |
| 2023 | 1,124 | 341 | 0% (0) | 6% | $223,371 |
| 2022 | 778 | 256 | 0% (0) | 5% | $108,868 |
| 2021 | 391 | 159 | 0% (0) | 4% | $19,308 |
| 2020 | 255 | 89 | 0% (0) | 11% | $131,966 |
| 2019 | 128 | 45 | 0% (0) | None | $23,977 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Dupixent | 14 | $54,249 | $3,875 |
| Clobetasol Propionate | 94 | $8,152 | $87 |
| Fluocinonide | 98 | $5,673 | $58 |
| Fluorouracil | 56 | $4,863 | $87 |
| Metronidazole | 38 | $3,239 | $85 |
| Ketoconazole | 103 | $2,144 | $21 |
| Clindamycin Phosphate | 53 | $2,021 | $38 |
| Tacrolimus | 13 | $1,981 | $152 |
| Doxycycline Hyclate | 49 | $1,794 | $37 |
| Tretinoin | 14 | $1,792 | $128 |
| Triamcinolone Acetonide | 143 | $1,572 | $11 |
| Ciclopirox | 41 | $1,437 | $35 |
| Betamethasone Diprop Augmented | 18 | $1,294 | $72 |
| Nystatin | 60 | $772 | $13 |
| Mupirocin | 48 | $675 | $14 |
| Lidocaine Hcl Viscous | 16 | $660 | $41 |
| Gabapentin | 36 | $522 | $15 |
| Hydrocortisone | 88 | $472 | $5 |
| Hydroxychloroquine Sulfate | 13 | $308 | $24 |
| Valacyclovir | 15 | $283 | $19 |
| Minoxidil | 11 | $214 | $19 |
| Hydroxyzine | 14 | $168 | $12 |
2022: 16 drugs
| Fluocinonide | 81 | $4,880 | $60 |
| Clobetasol Propionate | 48 | $4,830 | $101 |
| Fluorouracil | 27 | $2,478 | $92 |
| Metronidazole | 29 | $2,453 | $85 |
| Ketoconazole | 86 | $1,988 | $23 |
| Triamcinolone Acetonide | 110 | $1,128 | $10 |
| Doxycycline Hyclate | 35 | $986 | $28 |
| Valacyclovir | 19 | $981 | $52 |
| Ciclopirox | 36 | $931 | $26 |
| Clindamycin Phosphate | 34 | $805 | $24 |
| Nystatin | 35 | $783 | $22 |
| Betamethasone Diprop Augmented | 12 | $706 | $59 |
| Hydrocortisone | 72 | $603 | $8 |
| Mupirocin | 43 | $439 | $10 |
| Hydroxyzine | 12 | $311 | $26 |
| Gabapentin | 19 | $238 | $13 |
2021: 10 drugs
| Fluocinonide | 46 | $2,946 | $64 |
| Clobetasol Propionate | 28 | $2,330 | $83 |
| Fluorouracil | 20 | $2,143 | $107 |
| Ketoconazole | 34 | $709 | $21 |
| Ciclopirox | 26 | $680 | $26 |
| Triamcinolone Acetonide | 49 | $601 | $12 |
| Doxycycline Hyclate | 16 | $579 | $36 |
| Nystatin | 27 | $382 | $14 |
| Mupirocin | 25 | $324 | $13 |
| Hydrocortisone | 43 | $282 | $7 |
2020: 7 drugs
| Clobetasol Propionate | 12 | $1,098 | $92 |
| Fluocinonide | 14 | $672 | $48 |
| Triamcinolone Acetonide | 29 | $670 | $23 |
| Doxycycline Hyclate | 14 | $628 | $45 |
| Ketoconazole | 31 | $452 | $15 |
| Hydrocortisone | 21 | $121 | $6 |
| Prednisone | 11 | $80 | $7 |
2019: 3 drugs
| Triamcinolone Acetonide | 14 | $307 | $22 |
| Mupirocin | 15 | $209 | $14 |
| Prednisone | 11 | $147 | $13 |
Money from drug and device companies
$28 in 2025
| 2025 | 1 | 1 | None | $28 |
| 2023 | 2 | 2 | None | $38 |
| 2019 | 2 | 2 | None | $128 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| STRATA Skin Sciences | Xtrac | $28 | 1 payment
|
See the published payment
| STRATA Skin Sciences | Meals · 2025-11-17 | Xtrac | $28 |
See earlier years (2023, 2019)
2023: $38
| Galderma Laboratories L.P. | None | $23 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2019: $128
| Allergan | None | $97 | 1 payment
|
| Amgen | Enbrel | $30 | 1 payment
|
Professional record
- NPI
- 1295197028
- Licence
- CA A151279California A151279: Current · expires 2027-04-30
- Trained
- Stanford University School of Medicine, 2016
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2016-03-22
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 751 S Bascom Ave, San Jose, CA, 95128